355 related articles for article (PubMed ID: 37528390)
1. Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials.
Zhang SL; Yi XF; Huang LT; Sun L; Ma JT; Han CB
BMC Cancer; 2023 Aug; 23(1):719. PubMed ID: 37528390
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P; Zhen H; Zhao H; Zhao L; Cao B
BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
[TBL] [Abstract][Full Text] [Related]
3. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
Frampton JE
Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.
Zhao N; Wu ZP; Yang J; Feng WN; Yang SL; Luo Y; Ye J; Wang F; Zhang XW; Xiao Y; Wu LL; Gu WQ
World J Surg Oncol; 2023 Feb; 21(1):45. PubMed ID: 36782320
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
Cheng H; Li XJ; Wang XJ; Chen ZW; Wang RQ; Zhong HC; Wu TC; Cao QD
Lung Cancer; 2019 Nov; 137():7-13. PubMed ID: 31520922
[TBL] [Abstract][Full Text] [Related]
6. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Adjuvant First-Generation TKIs versus Chemotherapy in Patients with Completely Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis.
Shen B; Wu D; Liu J; Yang Y
Cancer Invest; 2024 Jan; 42(1):63-74. PubMed ID: 38224061
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Adjuvant Setting for Patients with Resected Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer: A Meta-Analysis with 11 Trials.
Yin Q; Xun X; Yang G; Cui H; Liu H
Oncol Res Treat; 2021; 44(6):344-353. PubMed ID: 33951671
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer.
Cui R; Wei C; Li X; Jiang O
Medicine (Baltimore); 2022 Nov; 101(47):e31894. PubMed ID: 36451449
[TBL] [Abstract][Full Text] [Related]
11. The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis.
Lin C; Hu F; Chu H; Ren P; Ma S; Wang J; Bai J; Han X; Ma S
Thorac Cancer; 2021 Apr; 12(7):1084-1095. PubMed ID: 33660941
[TBL] [Abstract][Full Text] [Related]
12. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
13. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
[TBL] [Abstract][Full Text] [Related]
14. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
Wu YL; John T; Grohe C; Majem M; Goldman JW; Kim SW; Kato T; Laktionov K; Vu HV; Wang Z; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Atasoy A; Herbst RS; Tsuboi M
J Thorac Oncol; 2022 Mar; 17(3):423-433. PubMed ID: 34740861
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
Herbst RS; Wu YL; John T; Grohe C; Majem M; Wang J; Kato T; Goldman JW; Laktionov K; Kim SW; Yu CJ; Vu HV; Lu S; Lee KY; Mukhametshina G; Akewanlop C; de Marinis F; Bonanno L; Domine M; Shepherd FA; Urban D; Huang X; Bolanos A; Stachowiak M; Tsuboi M
J Clin Oncol; 2023 Apr; 41(10):1830-1840. PubMed ID: 36720083
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
Passaro A; Mok TSK; Attili I; Wu YL; Tsuboi M; de Marinis F; Peters S
JAMA Oncol; 2023 Aug; 9(8):1124-1131. PubMed ID: 37166792
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients.
Chen RL; Sun LL; Cao Y; Chen HR; Zhou JX; Gu CY; Zhang Y; Wang SY; Hou W; Lin LZ
Front Oncol; 2021; 11():629394. PubMed ID: 33912453
[TBL] [Abstract][Full Text] [Related]
18. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
Spaans JN; Goss GD
Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
[TBL] [Abstract][Full Text] [Related]
20. Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Ma JT; Guo YJ; Song J; Sun L; Zhang SL; Huang LT; Jing W; Zhao JZ; Han CB
Biomed Res Int; 2021; 2021():8850256. PubMed ID: 33575349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]